Comparative Pharmacology
Head-to-head clinical analysis: CODEINE SULFATE versus WESTADONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CODEINE SULFATE versus WESTADONE.
CODEINE SULFATE vs WESTADONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Codeine sulfate is a prodrug that is metabolized to morphine, which acts as a mu-opioid receptor agonist, producing analgesia by mimicking the action of endogenous opioids. It also binds to kappa and delta opioid receptors, leading to reduced neurotransmitter release and altered pain perception.
Mu-opioid receptor agonist; also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake.
15-60 mg orally every 4-6 hours as needed for pain; maximum 360 mg per day.
Oral: 2.5-10 mg every 4-6 hours as needed for pain; maximum 40 mg per day.
None Documented
None Documented
2.5-3.5 hours (terminal) in adults; prolonged in hepatic impairment (up to 5-6 hours) and elderly
Terminal elimination half-life: 15-60 hours (mean ~24 hours). Clinical context: Prolonged half-life supports once-daily dosing in opioid maintenance; accumulation occurs with repeated dosing due to long half-life.
Renal: 90% (as morphine, norcodeine, and codeine conjugates); Fecal: <10%; Biliary: minimal
Primarily renal (40-50% as unchanged methadone and its metabolites, 15-20% as metadone-N-oxide), biliary/fecal (5-10%).
Category D/X
Category C
Opioid Agonist
Opioid Agonist